George Lundberg, MD Contributing Editor at Cancer Commons

  •   George Lundberg, MD

    Memorial Sloan Kettering Cancer Center recently began recruiting patients for a phase 1 clinical trial to test a treatment in which an investigational cancer cell-killing virus called Telomelysin is directly injected into inoperable esophageal cancer tumors. Participating patients will receive this “cancer vaccine” alongside standard chemoradiation therapy.

    .

  •   George Lundberg, MD

    Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.

    .

  •   George Lundberg, MD

    This article from MedPage Today discusses recent study findings demonstrating that patients with complex cases of non-small cell lung cancer can benefit from the insights of a molecular tumor board.

    .

  •   George Lundberg, MD

    A news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.

    .

  •   George Lundberg, MD

    A blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer. 

    .

  •   George Lundberg, MD

    A story published by the Prostate Cancer Foundation outlines two new treatment options approved by the U.S. Food and Drug Administration (FDA) this year. The two medications, rucaparib and olaparib, each target specific mutations that may be found in a patient’s tumor, and each was approved for a specific type of prostate cancer.

    .

  •   George Lundberg, MD

    A story from Immuno-Oncology News covers new results from a phase 1 clinical trial that indicate promising safety and early efficacy of a treatment that combines the drug Keytruda and an experimental cancer vaccine for people with advanced melanoma.

    .

  •   George Lundberg, MD

    This scientific research paper published in JAMA Oncology reports results from a clinical trial in which the drugs nivolumab and ipilimumab showed promising safety and efficacy for people with advanced liver cancer who had previously received the drug sorafenib.

    .

  •   George Lundberg, MD

    This academic research paper from The New England Journal of Medicine reports results from a clinical trial in which a treatment that combines the drugs atezolizumab and bevacizumab improved both progression-free and overall survival for people with unresectable primary liver cancer.

    .

  •   George Lundberg, MD

    Article from The ASCO Post curated by Contributing Editor George Lundberg, MD, who notes: 

    Recent clinical trial results show that immunotherapy—a type of treatment that boosts the immune system to fight cancer—provided long-lasting, improved outcomes for patients with advanced cervical or endometrial cancer. These are important findings for difficult-to-treat cancers.

    .